Clinical calculator summary
FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026
Clinical calculator summary
FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026
This route implements the official FIGO 2026 score for confirmed post-molar gestational trophoblastic neoplasia or gestational choriocarcinoma at initial diagnosis and staging before treatment.
Evidence-based context for fast calculator use
- Purpose:
- Strict FIGO 2026 anatomical stage plus seven-factor modified WHO GTN score for initial pretreatment assessment.
- Population:
- patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment
- Factors:
- Diagnosis, Externally assigned FIGO 2026 anatomical stage, Age at GTN diagnosis, Most recent antecedent pregnancy, Completed months from most recent pregnancy, Pretreatment hCG near treatment initiation, Largest uterine or metastatic tumor, Highest-weight metastatic site
- Reference:
- Ngan HYS, et al. FIGO staging for gestational trophoblastic neoplasia: 2026. Int J Gynaecol Obstet. Published 2026-07-19. doi:10.1002/ijgo.71229.
FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026
Enter completed years; the score boundary is age 40.
Enter completed whole months; score bands are 0-3, 4-6, 7-12, and 13 or more.
Enter the raw pretreatment value; do not round it into a score band.
Use the largest measured uterine or metastatic lesion in centimetres.
Enter a whole-number lesion count; exclude the uterine tumor and count lung lesions only when at least 1 cm.
Clinical Context & Background
Seven-factor FIGO 2026 score: age + antecedent pregnancy + completed-month interval + pretreatment hCG + largest uterine/metastatic tumor + highest-weight listed metastatic site + number of metastases. Total 0-21.Reference Data
| Total score | FIGO 2026 band | Interpretation boundary |
|---|---|---|
| 0-6 | Low risk | Scores 5-6 remain low with source caution |
| 7-12 | High risk | No intermediate group |
| >=13 | Ultra-high risk | Specialist GTN-center interpretation |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026 when strict FIGO 2026 anatomical stage plus seven-factor modified WHO GTN score for initial pretreatment assessment.
- Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.
How To Interpret
- Interpret the displayed result using the calculator-specific formula and reference table, spanning 0-6 through >=13.
- A boundary result should prompt input verification and clinical review rather than false precision.
What To Do Next
- Confirm organ site, pathology, menopausal or postoperative context, imaging, biomarker assay, and specialist referral pathway.
- Document the inputs, result, timing, and clinical context so the assessment can be reproduced.
Limitations
- Adnexal-mass, cervical postoperative, endometrial, and ovarian cytoreduction models answer different clinical questions.
- The result supports clinician judgment and does not independently determine treatment.
Validated Population
patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment
How to apply this result
For a representative case, verify Diagnosis, Externally assigned FIGO 2026 anatomical stage, Age at GTN diagnosis, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through all nine visible production controls at FIGO 2026 Stage I:0, Stage IV:7, and Stage IV:13.
- The exact low/high score-7 and high/ultra-high score-13 transitions rendered with anatomical stage kept separate from the seven-factor total.
- No unexpected N/A, stale control, literal undefined/null value, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/figo-GTN-risk-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during route load.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/figo-GTN-risk.json.
: Browser input adapter corrected and reverified
- Accepted finite number values already normalized by the shared calculator form while retaining strict malformed-input rejection.
- No equation, cutoff, unit, classification, or applicability rule changed; calculator-specific verification and the calculator-wide browser-input audit passed.
: Input workflow simplified and revalidated
- Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
- Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
- Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.
: Model updated
- Replaced the historical generic eight-factor route with the official FIGO 2026 seven-factor model and removed previous failed chemotherapy from the contract.
- Added source-defined low 0-6, high 7-12, and ultra-high >=13 bands while preserving scores 5-6 as low with explicit source caution.
: Calculation and scope corrected
- Added raw unrounded age, completed-month interval, hCG, tumor size, listed metastatic site, and metastatic-count rules with exact equalities and immutable trace.
- Added confirmed-diagnosis, initial-pretreatment, externally assigned stage, complete-staging, compatible-imaging, metastasis consistency, and PSTT/ETT exclusion gates.
- Removed favorable defaults, pre-scored controls, coercion, extra-key summation, regimen directives, and survival or cure claims.
: Full validation completed
- Passed 15,104/15,104 deterministic implementation assertions: 32 identity/source/scope, 13,824 exhaustive combination, 96 raw boundary, 512 malformed, 256 applicability/stage, 192 UI/reset, 128 trace/language/immutability, and 64 registry/report/history checks.
- This is software implementation verification, not prospective clinical validation.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
When should FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026 be used?
Use it for patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment when all required inputs and the intended clinical setting are confirmed.
Can FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026 determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.